Science News
from research organizations

New molecular target to improve neuroblastoma treatment

Date:
May 19, 2017
Source:
University of the Basque Country
Summary:
A new study has served to identify some genetic mutations that will help to improve the treatment of neuroblastoma.
Share:
FULL STORY

Circos diagram showing concomitantly mutated genes and/or MYCN amplification.
Credit: Image courtesy of University of the Basque Country

The annual mortality rate in childhood cancer of the sympathetic nervous system, or neuroblastoma, is 10 per million between the ages of 0 and 4. The collaborative work between Basque and Valencian researchers has served to identify some genetic mutations that will help to improve the treatment of this disease.

Researchers at the Instituto de Investigación Sanitaria La Fe (Institute of Healthcare Research La Fe) in Valencia led by Jaime Font de Mora, in collaboration with José Luis Zugaza, an Ikerbasque researcher at the UPV/EHU-University of the Basque Country and the "Achucarro Basque Center for Neuroscience," have by means of NGS (Next Generation Sequencing) identified mutations in the Tiam1 gene that predict a better prognosis for neuroblastoma patients.

A neuroblastoma is a solid, extracranial tumor more frequent in childhood. It accounts for 7% of all paediatric cancers and is the cause of 15% of the total number of deaths resulting from oncological processes in childhood. The incidence of it ranges between 8 and 10 cases per million children. Family cases of neuroblastoma have been described but they are extremely rare. Right now, it is not known how this rare type of cancer originates.

The study reveals that these mutations that anticipate the progression of this disease are located in various Tiam1 domains related to the Ras and Rac GTPases and also with Myc; all these proteins are involved in the aetiology and progression of this type of cancer.

The results have been published in the journal Oncotarget, which specialises in works dealing with targets for different types of cancers. These results suggest that the signalosome controlled by Tiam1 may be essential in the development of the neuroblastoma and, therefore, Tiam1 is positioned as a target that could help to improve the effectiveness of neuroblastoma treatment.

The next step is to incorporate these studies into clinical practice to improve the tools and procedures in the diagnosis with a view to implementing earlier treatments for the children affected.


Story Source:

Materials provided by University of the Basque Country. Note: Content may be edited for style and length.


Journal Reference:

  1. Elena Sanmartín, Yania Yáñez, Victoria Fornés-Ferrer, José L. Zugaza, Adela Cañete, Victoria Castel, Jaime Font de Mora. TIAM1 variants improve clinical outcome in neuroblastoma. Oncotarget, 2017; DOI: 10.18632/oncotarget.16787

Cite This Page:

University of the Basque Country. "New molecular target to improve neuroblastoma treatment." ScienceDaily. ScienceDaily, 19 May 2017. <www.sciencedaily.com/releases/2017/05/170519131645.htm>.
University of the Basque Country. (2017, May 19). New molecular target to improve neuroblastoma treatment. ScienceDaily. Retrieved May 29, 2017 from www.sciencedaily.com/releases/2017/05/170519131645.htm
University of the Basque Country. "New molecular target to improve neuroblastoma treatment." ScienceDaily. www.sciencedaily.com/releases/2017/05/170519131645.htm (accessed May 29, 2017).

RELATED STORIES